FDA Lifts Hold on Intellia Therapeutics Trial, Refocusing Attention on Valuation Upside

The FDA has lifted the clinical hold on Intellia Therapeutics' Phase 3 trial of nexiguran ziclumeran for hereditary transthyretin amyloidosis with polyneuropathy. This decision allows Intellia to resume the pivotal study after agreeing with regulators on enhanced safety protocols. The update affects a key gene therapy candidate in Intellia's pipeline and is likely to draw close attention from investors and partners.